{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:48:47Z","timestamp":1790786927997,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-024-02298-4","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T11:01:42Z","timestamp":1727780502000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Glycerophospholipid-driven lipid metabolic reprogramming as a common key mechanism in the progression of human primary hepatocellular carcinoma and cholangiocarcinoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Yanran","family":"Bi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xihui","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanbin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunli","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiji","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junchao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqian","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengli","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiansong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfei","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"issue":"3","key":"2298_CR1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/liv.15152","volume":"42","author":"E Desjonqueres","year":"2022","unstructured":"Desjonqueres E, et al. Preneoplastic lesions in the liver: molecular insights and relevance for clinical practice. Liver Int. 2022;42(3):492\u2013506.","journal-title":"Liver Int"},{"issue":"1","key":"2298_CR2","doi-asserted-by":"publisher","first-page":"8290","DOI":"10.1038\/s41467-023-43749-3","volume":"14","author":"J Calderaro","year":"2023","unstructured":"Calderaro J, et al. Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma. Nat Commun. 2023;14(1):8290.","journal-title":"Nat Commun"},{"issue":"5","key":"2298_CR3","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1097\/HEP.0000000000000005","volume":"78","author":"F Yang","year":"2023","unstructured":"Yang F, et al. Metabolic reprogramming and its clinical implication for liver cancer. Hepatology. 2023;78(5):1602\u201324.","journal-title":"Hepatology"},{"issue":"3","key":"2298_CR4","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jhep.2022.04.038","volume":"77","author":"C Raggi","year":"2022","unstructured":"Raggi C, et al. Metabolic reprogramming in cholangiocarcinoma. J Hepatol. 2022;77(3):849\u201364.","journal-title":"J Hepatol"},{"issue":"6487","key":"2298_CR5","doi-asserted-by":"publisher","first-page":"eaaw5473","DOI":"10.1126\/science.aaw5473","volume":"368","author":"B Faubert","year":"2020","unstructured":"Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368(6487):eaaw5473.","journal-title":"Science"},{"issue":"3","key":"2298_CR6","doi-asserted-by":"publisher","first-page":"e12772","DOI":"10.1111\/cpr.12772","volume":"53","author":"B Hu","year":"2020","unstructured":"Hu B, Lin JZ, Yang XB, Sang XT. Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvironment: a review. Cell Prolif. 2020;53(3):e12772.","journal-title":"Cell Prolif"},{"issue":"6","key":"2298_CR7","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.7150\/thno.82920","volume":"13","author":"K Yang","year":"2023","unstructured":"Yang K, et al. The role of lipid metabolic reprogramming in tumor microenvironment. Theranostics. 2023;13(6):1774\u2013808.","journal-title":"Theranostics"},{"issue":"1","key":"2298_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13045-024-01527-8","volume":"17","author":"J Lin","year":"2024","unstructured":"Lin J, Rao D, Zhang M, Gao Q. Metabolic reprogramming in the tumor microenvironment of liver cancer. J Hematol Oncol. 2024;17(1):6.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2298_CR9","doi-asserted-by":"publisher","first-page":"188314","DOI":"10.1016\/j.bbcan.2019.188314","volume":"1873","author":"D Anwanwan","year":"2020","unstructured":"Anwanwan D, et al. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2020;1873(1):188314.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"7","key":"2298_CR10","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1080\/15548627.2019.1580105","volume":"15","author":"X Huang","year":"2019","unstructured":"Huang X, et al. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance. Autophagy. 2019;15(7):1258\u201379.","journal-title":"Autophagy"},{"issue":"4","key":"2298_CR11","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41419-022-04821-w","volume":"13","author":"L Zhao","year":"2022","unstructured":"Zhao L, et al. Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer. Cell Death Dis. 2022;13(4):378.","journal-title":"Cell Death Dis"},{"issue":"15","key":"2298_CR12","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.2174\/13816128113199990489","volume":"20","author":"NH Dang","year":"2014","unstructured":"Dang NH, et al. Targeted cancer therapeutics: biosynthetic and energetic pathways characterized by metabolomics and the interplay with key cancer regulatory factors. Curr Pharm Des. 2014;20(15):2637\u201347.","journal-title":"Curr Pharm Des"},{"key":"2298_CR13","doi-asserted-by":"publisher","first-page":"763902","DOI":"10.3389\/fmolb.2021.763902","volume":"8","author":"J Han","year":"2021","unstructured":"Han J, Li Q, Chen Y, Yang Y. Recent Metabolomics Analysis in Tumor Metabolism Reprogramming. Front Mol Biosci. 2021;8:763902.","journal-title":"Front Mol Biosci"},{"issue":"3","key":"2298_CR14","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/hep.31391","volume":"73","author":"Z Hall","year":"2021","unstructured":"Hall Z, et al. Lipid remodeling in hepatocyte proliferation and hepatocellular carcinoma. Hepatology. 2021;73(3):1028\u201344.","journal-title":"Hepatology"},{"issue":"6","key":"2298_CR15","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1002\/hep.32344","volume":"76","author":"M de Gauna Ruiz","year":"2022","unstructured":"de Gauna Ruiz M, et al. Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids. Hepatology. 2022;76(6):1617\u201333.","journal-title":"Hepatology"},{"issue":"12","key":"2298_CR16","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41575-019-0217-8","volume":"16","author":"L Satriano","year":"2019","unstructured":"Satriano L, et al. Metabolic rearrangements in primary liver cancers: cause and consequences. Nat Rev Gastroenterol Hepatol. 2019;16(12):748\u201366.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2298_CR17","doi-asserted-by":"publisher","first-page":"216396","DOI":"10.1016\/j.canlet.2023.216396","volume":"575","author":"Z Luo","year":"2023","unstructured":"Luo Z, Eichinger KM, Zhang A, Li S. Targeting cancer metabolic pathways for improving chemotherapy and immunotherapy. Cancer Lett. 2023;575:216396.","journal-title":"Cancer Lett"},{"key":"2298_CR18","doi-asserted-by":"publisher","first-page":"114963","DOI":"10.1016\/j.biopha.2023.114963","volume":"164","author":"S Chen","year":"2023","unstructured":"Chen S, Duan H, Sun G. Reshaping immunometabolism in the tumour microenvironment to improve cancer immunotherapy. Biomed Pharmacother. 2023;164:114963.","journal-title":"Biomed Pharmacother"},{"key":"2298_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.canlet.2021.07.029","volume":"519","author":"H Li","year":"2021","unstructured":"Li H, et al. MiR-4310 regulates hepatocellular carcinoma growth and metastasis through lipid synthesis. Cancer Lett. 2021;519:161\u201371.","journal-title":"Cancer Lett"},{"issue":"1","key":"2298_CR20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/HEP.0000000000000784","volume":"80","author":"H Zhang","year":"2024","unstructured":"Zhang H, et al. Oleic acid-PPAR\u03b3-FABP4 loop fuels cholangiocarcinoma colonization in lymph node metastases microenvironment. Hepatology. 2024;80(1):69\u201386.","journal-title":"Hepatology"},{"issue":"Pt 3","key":"2298_CR21","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.semcancer.2022.02.004","volume":"86","author":"SLW Tan","year":"2022","unstructured":"Tan SLW, et al. The altered lipidome of hepatocellular carcinoma. Semin Cancer Biol. 2022;86(Pt 3):445\u201356.","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"2298_CR22","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.cmet.2016.04.018","volume":"23","author":"S Shalapour","year":"2016","unstructured":"Shalapour S, Karin M. Fatty acid-induced T cell loss greases liver carcinogenesis. Cell Metab. 2016;23(5):759\u201361.","journal-title":"Cell Metab"},{"issue":"10","key":"2298_CR23","doi-asserted-by":"publisher","first-page":"e4112","DOI":"10.1002\/nbm.4112","volume":"32","author":"K Sonkar","year":"2019","unstructured":"Sonkar K, et al. Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer. NMR Biomed. 2019;32(10):e4112.","journal-title":"NMR Biomed"},{"issue":"5","key":"2298_CR24","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3390\/ijms20051149","volume":"20","author":"SH Law","year":"2019","unstructured":"Law SH, et al. An updated review of lysophosphatidylcholine metabolism in human diseases. Int J Mol Sci. 2019;20(5):1149.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2298_CR25","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jhep.2009.01.027","volume":"50","author":"M Vinciguerra","year":"2009","unstructured":"Vinciguerra M, et al. Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN. J Hepatol. 2009;50(6):1132\u201341.","journal-title":"J Hepatol"},{"key":"2298_CR26","doi-asserted-by":"publisher","first-page":"108245","DOI":"10.1016\/j.jnutbio.2019.108245","volume":"74","author":"CR Lin","year":"2019","unstructured":"Lin CR, et al. Omega-3 polyunsaturated fatty acids suppress metastatic features of human cholangiocarcinoma cells by suppressing twist. J Nutr Biochem. 2019;74:108245.","journal-title":"J Nutr Biochem"},{"issue":"4","key":"2298_CR27","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3390\/nu11040893","volume":"11","author":"BK Yun","year":"2019","unstructured":"Yun BK, et al. Potential nutritional and metabolomic advantages of high fat oral supplementation in pancreatectomized pancreaticobiliary cancer patients. Nutrients. 2019;11(4):893.","journal-title":"Nutrients"},{"issue":"6","key":"2298_CR28","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.3390\/antiox12061153","volume":"12","author":"DJ Lagal","year":"2023","unstructured":"Lagal DJ, et al. Loss of PRDX6 aborts proliferative and migratory signaling in hepatocarcinoma cell lines. Antioxidants (Basel). 2023;12(6):1153.","journal-title":"Antioxidants (Basel)"},{"key":"2298_CR29","doi-asserted-by":"publisher","first-page":"104398","DOI":"10.1016\/j.tifs.2024.104398","volume":"146","author":"F Ashkar","year":"2024","unstructured":"Ashkar F, Wu J. E-Cadherin and its signaling pathways: a novel target of dietary components in modulating cell migration and proliferation. Trends Food Sci Technol. 2024;146:104398.","journal-title":"Trends Food Sci Technol"},{"issue":"2","key":"2298_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1158\/1541-7786.MCR-08-0195","volume":"7","author":"A Ambesi","year":"2009","unstructured":"Ambesi A, McKeown-Longo PJ. Anastellin, the angiostatic fibronectin peptide, is a selective inhibitor of lysophospholipid signaling. Mol Cancer Res. 2009;7(2):255\u201365.","journal-title":"Mol Cancer Res"},{"issue":"12","key":"2298_CR31","doi-asserted-by":"publisher","first-page":"111000","DOI":"10.1016\/j.celrep.2022.111000","volume":"39","author":"R Hou","year":"2022","unstructured":"Hou R, et al. Targeting EP2 receptor with multifaceted mechanisms for high-risk neuroblastoma. Cell Rep. 2022;39(12):111000.","journal-title":"Cell Rep"},{"issue":"9","key":"2298_CR32","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.3390\/ijms22094297","volume":"22","author":"MT Ferreira","year":"2021","unstructured":"Ferreira MT, et al. Cyclooxygenase inhibition alters proliferative, migratory, and invasive properties of human glioblastoma cells in vitro. Int J Mol Sci. 2021;22(9):4297.","journal-title":"Int J Mol Sci"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-024-02298-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-024-02298-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-024-02298-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T23:09:16Z","timestamp":1732835356000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-024-02298-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2298"],"URL":"https:\/\/doi.org\/10.1186\/s12944-024-02298-4","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"assertion":[{"value":"18 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study retrospectively collected data on patients with HCC or CCA treated at the Fifth Affiliated Hospital of Wenzhou Medical University between January 2020 and December 2023, including tumor and adjacent non-tumor tissue samples. All tissues were obtained through surgical resection, following standard procedures to ensure sufficient tissue for metabolomic sequencing analysis. The study protocol was approved by the ethics committees of all participating centers and performed according to the Declaration of Helsinki. Ethical approval was granted by the Ethics Committee of the Fifth Affiliated Hospital of Wenzhou Medical University, approval number CTR20210090. All patients provided written informed consent for the use of their data for research purposes. For further inquiries and requests for experimental information, please contact the corresponding author.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"326"}}